Igalan attenuates sepsis-induced inflammation through covalent targeting of the NLRP3 inflammasome pathway

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Sepsis is a life-threatening condition with no targeted therapies for its underlying macrophage-driven inflammation.
• Macrophages are key players in sepsis pathogenesis, mediating dangerous systemic inflammatory responses.

Purpose of the Study:

• To identify and characterize a novel therapeutic agent targeting macrophage inflammatory pathways in sepsis.
• To investigate the mechanism of action of the natural compound Igalan on inflammasome activation.

Main Methods:

• In vitro studies on macrophage inflammatory cascades and oxidative stress.
• Mechanistic investigation of Igalan's covalent modification of the NLRP3 NACHT domain.
• In vivo efficacy studies in LPS-challenged zebrafish and murine sepsis models.

Main Results:

• Igalan selectively inhibits macrophage-mediated inflammation, alleviates oxidative stress, and preserves mitochondrial integrity.
• Igalan irreversibly suppresses NLRP3 inflammasome activation through covalent modification.
• Igalan demonstrates therapeutic potential by mitigating systemic inflammation and organ injury in vivo.

Conclusions:

• Igalan is a novel covalent NLRP3 inhibitor with significant therapeutic potential for sepsis treatment.
• Targeting NLRP3 inflammasome activation with Igalan represents a promising strategy for managing sepsis.